Table 3.
Replicating viral vector-based COVID-19 vaccines under various stages of clinical development.
| Vaccine | Developer | Country | Clinical Trial Registry No. | Clinical Trial Status | Viral Vector |
|---|---|---|---|---|---|
| Brilife (IIBR-100) | The Israel Institute for Biological Research (IIBR) | Israel | NCT04608305 | Phase I/II | Vesicular stomatitis virus |
| NeuroRx, Inc. in collaboration with Cromos, Brilife Georgia, Israel Institute for Biological Research | Georgia | NCT04990466 | Phase IIb/III | Vesicular stomatitis virus | |
| DelNS1-2019-nCoV-RBD-OPT1 | Wantai Biopharm | China | ChiCTR2000037782 | Phase I | H1N1 Influenza virus |
| China | ChiCTR2000039715 | Phase-II | H1N1 Influenza virus | ||
| Philippines | ChiCTR2100051391 | Phase III | H1N1 Influenza virus | ||
| AdCLD-CoV19 | Cellid Co., Ltd. | Republic of Korea | NCT04666012 | Phase I/IIa | Adenovirus |
| AV-COVID-19 | Aivita Biomedical, Inc. in collaboration with PT AIVITA Biomedika Indonesia, Kariadi Hospital, Central Army Hospital RSPAD Gatot Soebroto | Indonesia | NCT05007496 | Phase I/II | Autologous dendritic cells and lymphocytes (DCL) |
| Aivita Biomedical, Inc. | United States of America | NCT04386252 | Phase I/II | Autologous dendritic cells and lymphocytes (DCL) | |
| Indonesia-MoH in collaboration with Aivita Biomedical, Inc. | Indonesia | NCT04685603 NCT04690387 | Phase I | Autologous dendritic cells and lymphocytes (DCL) | |
| ERUCOV-VAC | The Health Institutes of Turkey in collaboration with TC Erciyes University | Turkey | NCT04691947 | Phase I | Whole-virion inactivated |
| NCT04824391 | Phase II | Whole-virion inactivated | |||
| COH04S1 | City of Hope Medical Center | United States of America | NCT04639466 | Phase I | Synthetically modified vaccinia Ankara (MVA) |
| NCT04977024 | Phase II | MVA |